Bank Of New York Mellon Corp Castle Biosciences Inc Transaction History

Bank Of New York Mellon Corp

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$19.47 - $28.49 $1.58 Million - $2.32 Million	81,368 New	81,368 $1.85 Billion
Q4 2022 Feb 14, 2023	BUY	$18.08 - $30.0 $1.5 Million - $2.49 Million	82,982 New	82,982 $1.95 Million
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $220,147 - $335,649	9,780 Added 13.73%	81,018 $2.11 Million
Q2 2022 Aug 15, 2022	SELL	$16.0 - $45.99 $490,368 - $1.41 Million	-30,648 Reduced 30.08%	71,238 $1.56 Million
Q1 2022 May 11, 2022	BUY	$33.17 - $46.98 $486,205 - $688,632	14,658 Added 16.8%	101,886 $4.57 Million

Q4 2021 Feb 11, 2022	SELL	$39.06 - $67.58 $49,606 - $85,826	-1,270 Reduced 1.44%	87,228 $3.74 Million
Q3 2021 Nov 12, 2021	BUY	$60.13 - $77.6 $429,508 - $554,296	7,143 Added 8.78%	88,498 $5.89 Million
Q2 2021 Aug 11, 2021	BUY	$50.07 - $76.78 $167,333 - $256,598	3,342 Added 4.28%	81,355 $5.97 Million
Q1 2021 May 13, 2021	SELL	$58.92 - $97.33 $431,589 - $712,942	-7,325 Reduced 8.58%	78,013 $5.34 Million
Q4 2020 Feb 09, 2021	SELL	$43.6 - $73.05 $293,689 - $492,064	-6,736 Reduced 7.32%	85,338 $5.73 Million
Q3 2020 Nov 12, 2020	BUY	$38.47 - $52.03 $1.4 Million - $1.89 Million	36,300 Added 65.08%	92,074 $4.74 Million
Q2 2020 Aug 12, 2020	BUY	$27.28 - $43.01 $223,832 - $352,897	8,205 Added 17.25%	55,774 $2.1 Million
Q1 2020 May 06, 2020	BUY	$23.08 - $35.53 $493,519 - $759,737	21,383 Added 81.66%	47,569 $1.42 Million
Q4 2019 Feb 14, 2020	BUY	$15.74 - $35.04 $412,167 - $917,557	26,186 New	26,186 $900,000

162

25.3M

82.2K

150K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $559M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.